Clinical Trial Update: Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer [Phase 1]

View source ↗

Summary

This Phase 1 trial update reports termination of the INBRX-105 in combination with pembrolizumab across multiple solid tumors, including head and neck squamous …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Adenocarcinoma
• Gastric Adenocarcinoma
• Head and Neck Squamous Cell Carcinoma
• Melanoma
• Nasopharyngeal Carcinoma
• Non-small Cell Lung Cancer
• Oropharyngeal Carcinoma
• Renal Cell Carcinoma

Drugs mentioned

• INBRX-105
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Inhibrx Biosciences, Inc | Conditions: Metastatic Solid Tumors, Non-small Cell Lung Cancer | Phase 1 | Status: TERMINATED